Appendix B. Symptom ratings in main study.
| Before | 3 min | 60 min | 118 min | 140 min | 330 min | 1440 min | |
|---|---|---|---|---|---|---|---|
| Rating 1. Discomfort in the eyes | |||||||
| Control | 0.0 (0–26) | 1.5 (0–37) | 0.0 (0–51) | 0.0 (0–42) | 0.0 (0–10) | 0.0 (0–33) | 0.0 (0–36) |
| 0.05 ppm ACR | 0.0 (0–8) | 0.0 (0–34) | 1.0 (0–49) | 1.5 (0–71) | 0.0 (0–26) | 0.0 (0–15) | 0.0 (0–26) |
| 0.1 ppm ACR | 0.0 (0–28) | 0.0 (0–34) | 6.0 (0–75) | 8.0 (0–71) | 0.0 (0–13) | 0.0 (0–34) | 0.0 (0–19) |
| EA | 0.5 (0–6) | 0.0 (0–26) | 0.5 (0–38) | 0.5 (0–31) | 0.5 (0–8) | 0.0 (0–26) | 0.0 (0–26) |
| EA + 0.05ppm ACR | 0.5 (0–6) | 0.0 (0–26) | 0.5 (0–49) | 3.0 (0–50) | 0.0 (0–26) | 0.5 (0–25) | 0.0 (0–9) |
| EA + 0.1 ppm ACR | 0.5 (0–16) | 0.5 (0–25) | 2.0 (0–70) | 4.5 (0–78) | 0.0 (0–16) | 0.0 (0–32) | 0.0 (0–47) |
| Rating 2. Discomfort in the nose | |||||||
| Control | 0.0 (0–20) | 1.0 (0–26) | 1.0 (0–35) | 1.5 (0–49) | 0.0 (0–26) | 0.0 (0–26) | 1.5 (0–26) |
| 0.05 ppm ACR | 0.0 (0–30) | 1.0 (0–33) | 2.5 (0–26) | 1.5 (0–49) | 1.0 (0–49) | 0.0 (0–49) | 0.5 (0–26) |
| 0.1 ppm ACR | 0.0 (0–28) | 0.5 (0–24) | 3.5 (0–26) | 3.0 (0–49) | 2.5 (0–49) | 0.0 (0–26) | 0.0 (0–32) |
| EA | 0.0 (0–26) | 3.0 (0–39) | 1.5 (0–31) | 0.5 (0–37) | 0.5 (0–32) | 0.0 (0–26) | 0.0 (0–23) |
| EA + 0.05ppm ACR | 1.5 (0–26) | 1.0 (0–26) | 1.0 (0–49) | 0.5 (0–49) | 1.5 (0–48) | 0.5 (0–38) | 0.0 (0–26) |
| EA + 0.1 ppm ACR | 2.5 (0–30) | 4.0 (0–48) | 3.0 (0–49) | 4.5 (0–37) | 3.5 (0–50) | 0.5 (0–26) | 0.5 (0–26) |
| Rating 3. Discomfort in the throat | |||||||
| Control | 1.5 (0–20) | 0.5 (0–23) | 0.0 (0–43) | 3.0 (0–40) | 1.0 (0–61) | 0.0 (0–32) | 0.0 (0–64) |
| 0.05 ppm ACR | 1.5 (0–23) | 0.0 (0–24) | 3.5 (0–28) | 3.5 (0–22) | 7.0 (0–50) | 0.0 (0–25) | 0.0 (0–25) |
| 0.1 ppm ACR | 2.0 (0–25) | 0.0 (0–18) | 5.0 (0–20) | 1.0 (0–28) | 2.5 (0–23) | 0.0 (0–6) | 0.0 (0–6) |
| EA | 0.0 (0–16) | 0.0 (0–15) | 0.0 (0–49) | 0.0 (0–34) | 1.0 (0–35) | 0.0 (0–15) | 0.0 (0–14) |
| EA + 0.05ppm ACR | 3.0 (0–58) | 2.0 (0–28) | 1.0 (0–57) | 0.0 (0–38) | 3.0 (0–68) | 0.0 (0–37) | 1.0 (0–70) |
| EA + 0.1 ppm ACR | 0.0 (0–26) | 0.0 (0–17) | 0.0 (0–16) | 0.0 (0–31) | 1.5 (0–26) | 0.0 (0–11) | 0.0 (0–35) |
| Rating 4. Breathing difficulty | |||||||
| Control | 0.0 (0–26) | 0.0 (0–26) | 0.0 (0–34) | 0.0 (0–30) | 0.0 (0–57) | 0.0 (0–26) | 0.0 (0–50) |
| 0.05 ppm ACR | 0.0 (0–23) | 0.0 (0–23) | 0.5 (0–48) | 0.0 (0–49) | 0.5 (0–49) | 0.0 (0–26) | 1.0 (0–26) |
| 0.1 ppm ACR | 0.0 (0–19) | 0.0 (0–9) | 0.0 (0–16) | 0.0 (0–16) | 1.0 (0–26) | 0.0 (0–6) | 0.0 (0–8) |
| EA | 0.0 (0–6) | 0.0 (0–14) | 0.0 (0–27) | 0.0 (0–32) | 0.5 (0–59) | 0.0 (0–29) | 0.0 (0–26) |
| EA + 0.05ppm ACR | 0.0 (0–26) | 0.0 (0–26) | 0.0 (0–26) | 0.0 (0–49) | 0.0 (0–49) | 0.0 (0–26) | 0.0 (0–30) |
| EA + 0.1 ppm ACR | 0.0 (0–26) | 1.0 (0–26) | 0.0 (0–49) | 0.0 (0–49) | 0.5 (0–26) | 0.0 (0–26) | 0.0 (0–26) |
| Rating 5. Solvent smell | |||||||
| Control | 0.0 (0–6) | 5.0 (0–50) | 0.5 (0–26) | 1.5 (0–37) | 0.0 (0–29) | 0.0 (0–10) | 0.0 (0–6) |
| 0.05 ppm ACR | 0.0 (0–9) | 6.0 (0–34) | 5.0 (0–58) | 2.5 (0–26) | 0.0 (0–6) | 0.0 (0–11) | 0.0 (0–14) |
| 0.1 ppm ACR | 0.0 (0–6) | 6.0 (0–49) | 5.5 (0–48) | 3.0 (0–26) | 0.0 (0–6) | 0.0 (0–11) | 0.0 (0–14) |
| EA | 0.0 (0–6) | 26.0 (0–70) | 15.5 (0–48) | 23.0 (0–35) | 0.0 (0–6) | 0.0 (0–16) | 0.0 (0–10) |
| EA + 0.05ppm ACR | 0.0 (0–6) | 24.5 (0–63) | 6.0 (0–60) | 6.0 (0–53) | 0.0 (0–26) | 0.0 (0–6) | 0.0 (0–3) |
| EA + 0.1 ppm ACR | 0.0 (0–4) | 7.0 (0–70) | 6.0 (0–53) | 5.5 (0–56) | 0.0 (0–10) | 0.0 (0–5) | 0.0 (0–1) |
| Rating 6. Headache | |||||||
| Control | 0.0 (0–25) | 0.0 (0–12) | 0.0 (0–25) | 0.0 (0–25) | 0.0 (0–25) | 0.0 (0–50) | 0.0 (0–11) |
| 0.05 ppm ACR | 0.0 (0–9) | 0.0 (0–26) | 0.5 (0–41) | 0.0 (0–40) | 1.5 (0–26) | 0.0 (0–26) | 0.0 (0–26) |
| 0.1 ppm ACR | 0.0 (0–10) | 0.5 (0–12) | 0.0 (0–27) | 0.0 (0–26) | 0.0(0–21) | 0.0 (0–11) | 0.0 (0–15) |
| EA | 0.0 (0–18) | 0.0 (0–19) | 0.0 (0–49) | 0.0 (0–26) | 0.0 (0–18) | 0.5 (0–48) | 0.0 (0–14) |
| EA + 0.05ppm ACR | 0.0 (0–25) | 0.0 (0–11) | 0.0 (0–26) | 0.0 (0–37) | 0.0 (0–43) | 0.0 (0–53) | 0.0 (0–30) |
| EA + 0.1 ppm ACR | 0.0 (0–26) | 0.5 (0–25) | 1.0 (0–27) | 0.0 (0–9) | 0.5 (0–26) | 0.0 (0–26) | 0.0 (0–25) |
| Rating 7. Fatigue | |||||||
| Control | 5.5 (0–26) | 2.5 (0–32) | 3.0 (0–51) | 11.0 (0–55) | 5.0 (0–28) | 4.5 (0–49) | 4.5 (0–49) |
| 0.05 ppm ACR | 7.0 (0–49) | 8.0 (0–49) | 22.5 (0–60) | 9.5 (0–49) | 6.0 (0–30) | 5.0 (0–42) | 10.5 (0–36) |
| 0.1 ppm ACR | 6.0 (0–28) | 4.5 (0–70) | 6.0 (0–93) | 6.0 (0–90) | 4.0 (0–49) | 6.0 (0–62) | 2.5 (0–35) |
| EA | 6.0 (0–71) | 6.0 (0–72) | 6.0 (0–100) | 5.5 (0–100) | 0.5 (0–90) | 1.5 (0–73) | 1.0 (0–26) |
| EA + 0.05ppm ACR | 6.0 (0–49) | 5.5 (0–45) | 13.5 (0–71) | 16.0 (0–68) | 5.0 (0–47) | 4.0 (0–48) | 3.0 (0–51) |
| EA + 0.1 ppm ACR | 6.0 (0–49) | 4.5 (0–54) | 6.0 (0–50) | 6.0 (0–34) | 3.5 (0–26) | 2.5 (0–55) | 3.5 (0–29) |
| Rating 8. Nausea | |||||||
| Control | 0.0 (0–25) | 0.0 (0–19) | 0.0 (0–19) | 0.0 (0–46) | 0.0 (0–14) | 0.0 (0–12) | 0.0 (0–29) |
| 0.05 ppm ACR | 0.0 (0–26) | 0.0 (0–26) | 0.0 (0–18) | 0.0 (0–15) | 0.0 (0–15) | 0.0 (0–20) | 0.0 (0–17) |
| 0.1 ppm ACR | 0.0 (0–20) | 0.0 (0–13) | 0.0 (0–15) | 0.0 (0–20) | 0.0 (0–15) | 0.0 (0–10) | 0.0 (0–9) |
| EA | 0.0 (0–17) | 0.0 (0–11) | 0.0 (0–19) | 0.0 (0–54) | 0.0 (0–12) | 0.0 (0–8) | 0.0 (0–13) |
| EA + 0.05ppm ACR | 0.0 (0–11) | 0.0 (0–10) | 0.0 (0–27) | 0.0 (0–26) | 0.0 (0–11) | 0.0 (0–6) | 0.0 (0–25) |
| EA + 0.1 ppm ACR | 0.0 (0–21) | 0.0 (0–15) | 0.0 (0–11) | 0.0 (0–5) | 0.0 (0–5) | 0.0 (0–4) | 0.0 (0–23) |
| Rating 9. Dizziness | |||||||
| Control | 0.0 (0–7) | 0.0 (0–10) | 0.0 (0–13) | 0.0 (0–10) | 0.0 (0–6) | 0.0 (0–20) | 0.0 (0–8) |
| 0.05 ppm ACR | 0.0 (0–15) | 0.0 (0–26) | 0.0 (0–27) | 0.0 (0–9) | 0.0 (0–16) | 0.0 (0–11) | 0.0 (0–9) |
| 0.1 ppm ACR | 0.0 (0–13) | 0.0 (0–9) | 0.0 (0–15) | 0.0 (0–9) | 0.0 (0–26) | 0.0 (0–6) | 0.0 (0–6) |
| EA | 0.0 (0–14) | 0.0 (0–9) | 0.0 (0–11) | 0.0 (0–28) | 0.0 (0–57) | 0.0 (0–26) | 0.0 (0–5) |
| EA + 0.05ppm ACR | 0.0 (0–14) | 0.0 (0–12) | 0.0 (0–23) | 0.0 (0–18) | 0.0 (0–23) | 0.0 (0–14) | 0.0 (0–11) |
| EA + 0.1 ppm ACR | 0.0 (0–10) | 0.0 (0–5) | 0.0 (0–4) | 0.0 (0–15) | 0.0 (0–37) | 0.0 (0–4) | 0.0 (0–4) |
| Rating 10. Feeling of intoxication | |||||||
| Control | 0.0 (0–6) | 0.0 (0–10) | 0.0 (0–6) | 0.0 (0–6) | 0.0 (0–6) | 0.0 (0–10) | 0.0 (0–5) |
| 0.05 ppm ACR | 0.0 (0–3) | 0.0 (0–6) | 0.0 (0–8) | 0.0 (0–9) | 0.0 (0–3) | 0.0 (0–9) | 0.0 (0–3) |
| 0.1 ppm ACR | 0.0 (0–14) | 0.0 (0–6) | 0.0 (0–12) | 0.5 (0–6) | 0.0 (0–6) | 0.0 (0–6) | 0.0 (0–6) |
| EA | 0.0 (0–11) | 0.0 (0–6) | 0.0 (0–37) | 0.0 (0–62) | 0.0 (0–27) | 0.0 (0–26) | 0.0 (0–4) |
| EA + 0.05ppm ACR | 0.0 (0–6) | 0.0 (0–6) | 0.0 (0–8) | 0.0 (0–6) | 0.0 (0–4) | 0.0 (0–5) | 0.0 (0–3) |
| EA + 0.1 ppm ACR | 0.0 (0–3) | 0.0 (0–4) | 0.0 (0–4) | 0.0 (0–7) | 0.0 (0–3) | 0.0 (0–3) | 0.0 (0–4) |
Results of symptom ratings of 18 volunteers measured before, 3 min, 60 min, 118 min, 140 min, 330 min, and 1440 min after a 2 h exposure to 0 ppm (control exposure), 0.05 and 0.1 ppm of acrolein and ethyl acetate (EA) (15 ppm, control exposure), EA + low acrolein and EA + high acrolein. Values are given as median with range in parentheses.